Loss of the PGE2 receptor EP1 enhances bone acquisition, which protects against age and ovariectomy-induced impairments in bone strength.

[1]  S. Doré,et al.  Contribution of PGE2 EP1 receptor in hemin-induced neurotoxicity , 2013, Front. Mol. Neurosci..

[2]  S. Doré,et al.  PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease , 2012, Neurobiology of Aging.

[3]  E. Schwarz,et al.  EP1−/− Mice Have Enhanced Osteoblast Differentiation and Accelerated Fracture Repair , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  S. Boonen,et al.  Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time‐specific actions of sex steroids and IGF‐1: Evidence from pubertal mouse models , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  J. Puzas,et al.  Axin2 controls bone remodeling through the β-catenin–BMP signaling pathway in adult mice , 2009, Journal of Cell Science.

[6]  R. Guldberg,et al.  Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4. , 2009, The American journal of pathology.

[7]  C. Bult,et al.  Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels , 2009, Aging cell.

[8]  L. Zon,et al.  Genetic Interaction of PGE2 and Wnt Signaling Regulates Developmental Specification of Stem Cells and Regeneration , 2009, Cell.

[9]  Hicham Drissi,et al.  Reduced COX-2 Expression in Aged Mice Is Associated With Impaired Fracture Healing , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  C. Iadecola,et al.  Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway , 2008, Neurobiology of Disease.

[11]  R. Jilka,et al.  Extracellular Matrix Made by Bone Marrow Cells Facilitates Expansion of Marrow‐Derived Mesenchymal Progenitor Cells and Prevents Their Differentiation Into Osteoblasts , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  Yuan-sheng Gao,et al.  Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. , 2007, The Journal of clinical investigation.

[13]  M. Wiles,et al.  Know thy mouse. , 2006, Trends in genetics : TIG.

[14]  D. Thompson,et al.  Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice. , 2005, Bone.

[15]  Ego Seeman,et al.  Sexual Dimorphism in Skeletal Size, Density and Strength , 2004 .

[16]  E. Schwarz,et al.  PGE2 inhibits chondrocyte differentiation through PKA and PKC signaling. , 2004, Experimental cell research.

[17]  S. Narumiya,et al.  Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Regan,et al.  Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 * , 2002, The Journal of Biological Chemistry.

[19]  C. Leu,et al.  Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2). , 2001, Molecular pharmacology.

[20]  P Geusens,et al.  Risk of new vertebral fracture in the year following a fracture. , 2001, JAMA.

[21]  M. Kumegawa,et al.  Prostaglandin E2 Directly Inhibits Bone-Resorbing Activity of Isolated Mature Osteoclasts Mainly Through the EP4 Receptor , 2000, Calcified Tissue International.

[22]  S. Narumiya,et al.  Impaired Bone Resorption to Prostaglandin E2 in Prostaglandin E Receptor EP4-knockout Mice* , 2000, The Journal of Biological Chemistry.

[23]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[24]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[25]  S. Narumiya,et al.  Prostaglandin E receptor subtypes in mouse osteoblastic cell line. , 1996, Endocrinology.

[26]  L. Melton,et al.  The worldwide problem of osteoporosis: insights afforded by epidemiology. , 1995, Bone.

[27]  Robert Epstein,et al.  Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  S. H. Kan,et al.  Epidemiology of vertebral fractures in women. , 1989, American journal of epidemiology.

[29]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.